Urogen Pharma Rg

UroGen Pharma develops proprietary RTGel and Jelmyto for non‑muscle invasive urothelial cancers, with Phase‑III UGN‑102, UGN‑103/104 and Phase‑I UGN‑301 programs supported by licenses with Agenus, Allergan, MD Anderson, and Johns Hopkins.

Headquarters: Israel (ISR)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 287
HQ: Princeton

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
URGN	Urogen Pharma Rg Cap: 1.0B	EQUITY	NGM	USD	IL0011407140	Active	📈